Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression

Blood Cancer Journal

Volumn 2, Issue 1, 2012, Pages

  Niapour, M ^a   Farr, C ^a,b   Minden, M ^c   Berger, S A ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

AML; Calpain; Calpastatin

Indexed keywords

ANTILEUKEMIC AGENT; CALPAIN; CALPASTATIN; CD34 ANTIGEN; CD38 ANTIGEN; CYTARABINE; DAUNORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PD 150606; RAS PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BLAST CELL; CLINICAL ARTICLE; CONTINUOUS INFUSION; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; PROTEIN EXPRESSION; PROTEIN MICROARRAY; TREATMENT RESPONSE;

EID: 84863902785     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.50     Document Type: Article

References (64)

1. Tallman MS. Relevance of pathologic classifications and diagnosis of acute myeloid leukemia to clinical trials and clinical practice. Cancer Treat Res 2004; 121: 45-67.
2. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005; 23: 6285-6295. (Pubitemid 46218838)
3. Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 2004; 89: 998-1008. (Pubitemid 39049910)
4. Li H, Thompson VF, Goll DE. Effects of autolysis on properties of mu-and m-calpain. Biochim Biophys Acta 2004; 1691: 91-103. (Pubitemid 38521270)
5. Averna M, Stifanese R, De Tullio R, Passalacqua M, Defranchi E, Salamino F et al. Regulation of calpain activity in rat brain with altered Ca2+ homeostasis. J Biol Chem 2007; 282: 2656-2665. (Pubitemid 47076753)
6. Hassen GW, Feliberti J, Kesner L, Stracher A, Mokhtarian F. A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. J Neuroimmunol 2006; 180: 135-146. (Pubitemid 44692330)
7. Mellgren RL, Zhang W, Miyake K, McNeil PL. Calpain is required for the rapid, calcium-dependent repair of wounded plasma membrane. J Biol Chem 2007; 282: 2567-2575. (Pubitemid 47076799)
8. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003; 83: 731-801. (Pubitemid 36828925)
9. Shao H, Chou J, Baty CJ, Burke NA, Watkins SC, Stolz DB et al. Spatial localization of m-calpain to the plasma membrane by phosphoinositide biphosphate binding during epidermal growth factor receptor-mediated activation. Mol Cell Biol 2006; 26: 5481-5496. (Pubitemid 44036214)
10. Razeghi P, Volpini KC, Wang ME, Youker KA, Stepkowski S, Taegtmeyer H. Mechanical unloading of the heart activates the calpain system. J Mol Cell Cardiol 2007; 42: 449-452. (Pubitemid 46156947)
11. Vermaelen M, Sirvent P, Raynaud F, Astier C, Mercier J, Lacampagne A et al. Differential localization of autolyzed calpains 1 and 2 in slow and fast skeletal muscles in the early phase of atrophy. Am J Physiol Cell Physiol 2007; 292: C1723-C1731. (Pubitemid 47080549)
12. Betts R, Anagli J. The beta-and gamma-CH2 of B27-WT's Leu11 and Ile18 side chains play a direct role in calpain inhibition. Biochemistry 2004; 43: 2596-2604. (Pubitemid 38327855)
13. Betts R, Weinsheimer S, Blouse GE, Anagli J. Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. J Biol Chem 2003; 278: 7800-7809. (Pubitemid 36800513)
14. Takano J, Tomioka M, Tsubuki S, Higuchi M, Iwata N, Itohara S et al. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J Biol Chem 2005; 280: 16175-16184. (Pubitemid 40616744)
15. Hood JL, Brooks WH, Roszman TL. Subcellular mobility of the calpain/calpastatin network: an organelle transient. Bioessays 2006; 28: 850-859. (Pubitemid 44433747)
16. Stifanese R, Averna M, Salamino F, Cantoni C, Mingari MC, Prato C et al. Characterization of the calpain/calpastatin system in human hemopoietic cell lines. Arch Biochem Biophys 2006; 456: 48-57. (Pubitemid 44820022)
17. Hanna RA, Garcia-Diaz BE, Davies PL. Calpastatin simultaneously binds four calpains with different kinetic constants. FEBS Lett 2007; 581: 2894-2898. (Pubitemid 46899031)
18. Kim KA, Lee YA, Shin MH. Calpain-dependent calpastatin cleavage regulates caspase-3 activation during apoptosis of Jurkat T cells induced by Entamoeba histolytica. Int J Parasitol 2007; 37: 1209-1219. (Pubitemid 47096726)
19. Perrin BJ, Huttenlocher A. Calpain. Int J Biochem Cell Biol 2002; 34: 722-725. (Pubitemid 34304162)
20. Benetti R, Del Sal G, Monte M, Paroni G, Brancolini C, Schneider C. The death substrate Gas2 binds m-calpain and increases susceptibility to p53-dependent apoptosis. EMBO J 2001; 20: 2702-2714. (Pubitemid 32938555)
21. Benetti R, Copetti T, Dell'Orso S, Melloni E, Brancolini C, Monte M et al. The calpain system is involved in the constitutive regulation of beta-catenin signaling functions. J Biol Chem 2005; 280: 22070-22080. (Pubitemid 40827862)
22. Demarchi F, Bertoli C, Copetti T, Tanida I, Brancolini C, Eskelinen EL et al. Calpain is required for macroautophagy in mammalian cells. J Cell Biol 2006; 175: 595-605. (Pubitemid 44790613)
23. Hirano M, Osada S, Aoki T, Hirai S, Hosaka M, Inoue J et al. MEK kinase is involved in tumor necrosis factor alpha-induced NF-kappaB activation and degradation of IkappaB-alpha. J Biol Chem 1996; 271: 13234-13238.
24. Glading A, Chang P, Lauffenburger DA, Wells A. Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway. J Biol Chem 2000; 275: 2390-2398. (Pubitemid 30081997)
25. Glading A, Uberall F, Keyse SM, Lauffenburger DA, Wells A. Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling. J Biol Chem 2001; 276: 23341-23348.
26. Leloup L, Daury L, Mazeres G, Cottin P, Brustis JJ. Involvement of the ERK/MAP kinase signalling pathway in milli-calpain activation and myogenic cell migration. Int J Biochem Cell Biol 2007; 39: 1177-1189. (Pubitemid 46819136)
27. Niapour M, Berger S. Flow cytometric measurement of calpain activity in living cells. Cytometry A 2007; 71: 475-485. (Pubitemid 47036038)
28. Tanaka K, Takechi M, Nishimura S, Oguma N, Kamada N. Amplification of c-MYC oncogene and point mutation of N-RAS oncogene point mutation in acute myelocytic leukemias with double minute chromosomes. Leukemia 1993; 7: 469-471. (Pubitemid 23093110)
29. Morgan MA, Dolp O, Reuter CW. Cell-cycle-dependent activation of mitogenactivated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood 2001; 97: 1823-1834. (Pubitemid 32217252)
30. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004; 64: 6461-6468. (Pubitemid 39297901)
31. Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C et al. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 2005; 105: 1706-1716. (Pubitemid 40223694)
32. Ricciardi MR, McQueen T, Chism D, Milella M, Estey E, Kaldjian E et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 2005; 19: 1543-1549. (Pubitemid 43090397)
33. Bardet V, Tamburini J, Ifrah N, Dreyfus F, Mayeux P, Bouscary D et al. Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica 2006; 91: 757-764. (Pubitemid 44014541)
34. Kojima K, Konopleva M, Samudio IJ, Ruvolo V, Andreeff M. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res 2007; 67: 3210-3219. (Pubitemid 46724859)
35. Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C et al. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood 2007; 109: 2121-2129. (Pubitemid 46348214)
36. Samantaray S, Ray SK, Ali SF, Banik NL. Calpain activation in apoptosis of motoneurons in cell culture models of experimental parkinsonism. Ann NY Acad Sci 2006; 1074: 349-356. (Pubitemid 44532839)
37. Galvez AS, Diwan A, Odley AM, Hahn HS, Osinska H, Melendez JG et al. Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. Circ Res 2007; 100: 1071-1078. (Pubitemid 46598932)
38. Matsubara E, Tsuchiya A, Minami N, Nishino I, Pappolla MA, Shoji M et al. A unique case of limb-girdle muscular dystrophy type 2A carrying novel compound heterozygous mutations in the human CAPN3 gene. Eur J Neurol 2007; 14: 819-822. (Pubitemid 47012176)
39. Yang PM, Chen HC, Tsai JS, Lin LY. Cadmium induces Ca2+-dependent necrotic cell death through calpain-triggered mitochondrial depolarization and reactive oxygen species-mediated inhibition of nuclear factor-kappaB activity. Chem Res Toxicol 2007; 20: 406-415.
40. Zhu W, Murtha PE, Young CY. Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. Biochem Biophys Res Commun 1995; 214: 1130-1137.
41. Zhu DM, Uckun FM. Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. Clin Cancer Res 2000; 6: 2456-2463. (Pubitemid 30399215)
42. Witkowski JM, Zmuda-Trzebiatowska E, Swiercz JM, Cichorek M, Ciepluch H, Lewandowski K et al. Modulation of the activity of calcium-activated neutral proteases (calpains) in chronic lymphocytic leukemia (B-CLL) cells. Blood 2002; 100: 1802-1809. (Pubitemid 34925160)
43. Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F et al. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005; 24: 4993-4999. (Pubitemid 41129103)
44. Guan N, Korukonda R, Hurh E, Schmittgen TD, Donkor IO, Dalton JT. Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. Int J Oncol 2006; 29: 655-663.
45. Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer 2011; 11: 364-374.
46. Niapour M, Yu Y, Berger SA. Regulation of calpain activity by c-Myc through calpastatin and promotion of transformation in c-Myc-negative cells by calpastatin suppression. J Biol Chem 2008; 283: 21371-21381.
47. Goy A, Gilles F. Update on the proteasome inhibitor bortezomib in hematologic malignancies. Clin Lymphoma 2004; 4: 230-237. (Pubitemid 38528878)
48. Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel J et al. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Oncology 2006; 70: 474-482. (Pubitemid 46333769)
49. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007; 109: 3177-3188. (Pubitemid 46572502)
50. Gutierrez NC, Lopez-Perez R, Hernandez JM, Isidro I, Gonzalez B, Delgado M et al. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 2005; 19: 402-409. (Pubitemid 40403317)
51. Sasaki T, Kikuchi T, Yumoto N, Yoshimura N, Murachi T. Comparative specificity and kinetic studies on porcine calpain I and calpain II with naturally occurring peptides and synthetic fluorogenic substrates. J Biol Chem 1984; 259: 12489-12494. (Pubitemid 15204828)
52. Rosser BG, Powers SP, Gores GJ. Calpain activity increases in hepatocytes following addition of ATP. Demonstration by a novel fluorescent approach. J Biol Chem 1993; 268: 23593-23600. (Pubitemid 23328091)
53. Wang KK, Nath R, Posner A, Raser KJ, Buroker-Kilgore M, Hajimohammadreza I et al. An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cellpermeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci USA 1996; 93: 6687-6692. (Pubitemid 26230370)
54. Soboloff J, Zhang Y, Minden M, Berger S. Sensitivity of myeloid leukemia cells to calcium influx blockade. Application to bone marrow purging. Exp Hematol 2002; 30: 1219.
55. Carragher NO, Westhoff MA, Riley D, Potter DA, Dutt P, Elce JS et al. v-Src-induced modulation of the calpain-calpastatin proteolytic system regulates transformation. Mol Cell Biol 2002; 22: 257-269. (Pubitemid 33144273)
56. Yajima Y, Kawashima S. Calpain function in the differentiation of mesenchymal stem cells. Biol Chem 2002; 383: 757-764. (Pubitemid 34649894)
57. Chen Z, Knutson E, Kurosky A, Albrecht T. Degradation of p21cip1 in cells productively infected with human cytomegalovirus. J Virol 2001; 75: 3613-3625. (Pubitemid 32246371)
58. Delmas C, Aragou N, Poussard S, Cottin P, Darbon JM, Manenti S. MAP kinasedependent degradation of p27Kip1 by calpains in choroidal melanoma cells. Requirement of p27Kip1 nuclear export. J Biol Chem 2003; 278: 12443-12451. (Pubitemid 36800231)
59. Kindle KB, Collins HM, Heery DM. MOZ-TIF2-mediated destruction of CBP/p300 is blocked by calpain inhibitor 2. Leukemia 2010; 24: 1359-1361.
60. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648. (Pubitemid 24067706)
61. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737. (Pubitemid 27298715)
62. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010; 115: 1976-1984.
63. Inazawa J, Nakagawa H, Misawa S, Abe T, Minoshima S, Fukuyama R et al. Assignment of the human calpastatin gene (CAST) to chromosome 5 at region q14-q22. Cytogenet Cell Genet 1990; 54: 156-158.
64. Herry A, Douet-Guilbert N, Gueganic N, Morel F, Le Bris MJ, Berthou C et al. Del(5q) and MLL amplification in homogeneously staining region in acute myeloblastic leukemia: a recurrent cytogenetic association. Ann Hematol 2006; 85: 244-249.